Back to search results

Direct Selective Laser Trabeculoplasty (DSLT) for Glaucoma or Ocular Hypertension

This study is looking at a new laser treatment called Direct Selective Laser Trabeculoplasty (DSLT) for people with high eye pressure (ocular hypertension) or a type of glaucoma called open-angle glaucoma. All participants in this study have already had a similar laser treatment called Selective Laser Trabeculoplasty (SLT). The goal is to see how safe and effective DSLT is at lowering eye pressure over six months. You could be eligible if you are between 18 and 80 years old, have ocular hypertension or open-angle glaucoma, have had SLT before, and have an eye pressure between 18 and 32 mmHg without medication.

Study design
This is a single-arm study, meaning all 60 participants will receive the same DSLT treatment. The study is designed to evaluate the safety and effectiveness of the treatment.
What's involved
You will undergo the DSLT procedure in one eye. Your eye pressure will be measured at the start of the study and for six months after the treatment.
Compensation
Not stated in the trial record.
Follow-up
Your eye pressure will be monitored for six months after the DSLT treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07589270

Direct Selective Laser Trabeculoplasty (DSLT) for Patients With Glaucoma or Ocular Hypertension Previously Treated With SLT

Not Yet Recruiting
NAAges 18–80InterventionalTreatment
The New York Eye Surgery Center
~60 participants
Updated 2026-05-15 on ClinicalTrials.gov
What's tested:DSLT

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Ocular Hypertension or Open-Angle Glaucoma Patients Previously Treated with Selective Laser Trabeculoplasty (SLT)
Measured over baseline through 6 months post DSLT treatment

Conditions

Ocular Hypertension Glaucoma
POAG

Explore related trials

Ocular HypertensionPrimary Open Angle Glaucoma

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Nathan Radcliffe, M.D. · PRINCIPAL_INVESTIGATOR · New York Eye Surgery Center

Who to contact

Krystina Tavarez Feliciano, B.A
[email protected]
718-519-1000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

• Adult patients (18-80 years old), scheduled to undergo DSLT treatment in one eye.
Diagnosis of ocular hypertension (OHTN) or primary open angle glaucoma (POAG).
Previous history of selective laser trabeculoplasty (SLT) treatment. • Medication free or washed out IOP at time 0 ranging from ≥ 18 through 32 mm Hg.

Exclusion

• Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0)
Previous glaucoma surgeries/interventions:
Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
Recent SLT failures (within 6 months of initial treatment).
Patients who have undergone cataract surgery within the prior 2 years.
Secondary glaucoma:
Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.

What this trial measures

  • Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Ocular Hypertension or Open-Angle Glaucoma Patients Previously Treated with Selective Laser Trabeculoplasty (SLT)baseline through 6 months post DSLT treatment

    IOP measured using Goldmann applanation tonometry. Washed-out IOP assessed at baseline prior to DSLT and at 6 months post-treatment following protocol-defined medication washout.